DAFTAR PUSTAKA
1.
Price SA, Wilson LM. Disfungsi Mekanis Jantung dan Bantuan Sirkulasi. Dalam : Hartanto H, Susi N, Wulansari P, Maharani DA, editor. Patofisiologi : Konsep Klinis Proses-Proses Penyakit Edisi 6. Jakarta: EGC; 2003: 632.
2.
Guyton AC, Hall JE. Gagal Jantung. Dalam : Rachman LY, Hartanto H, Novrianti A, Wulandari N, editor. Buku Ajar Fisiologi Kedokteran Edisi 11. Jakarta: EGC; 2006: 271.
3.
Fuster V, Walsh RA, Harrington RA. Pathophysiology of Heart Failure. Hurst's The Heart 13th Ed : McGraw Hill; 2011: 721.
4.
Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Heart Failure and Cor Pulmonale. Harrison's Principles of Internal Medicine 18th Ed : McGraw Hill; 2011: 1901.
5.
Firmansyah D. Asuhan Keperawatan Dengan Gagal Jantung di Ruang Sakura RSUD Sragen. Fakultas Keperawatan Universitas Muhammadiyah Semarang. 2009: 1-2.
6.
Fuster V, Walsh RA, Harrington RA. The Epidemiology and Diagnosis of Heart Failure. Hurst's The Heart , 13th ed. : McGraw Hill; 2011: 739.
7.
Braunwald E. Heart Failure and Cor Pulmonale. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principle of Internal Medicine . 16th Edition. New York: McGraw Hill; 2005: 535.
8.
Hersunarti N. Pedoman Diagnosis dan Pengobatan Gagal Jantung Kronik. Dalam Harimurti, GM. Aspek Metabolik Pada Penyakit Kardiovaskular. Jakarta. Bagian Kardiologi Fakultas Kedokteran Universitas Indonesia. 2002: 1.
9.
Joesoef A. Gagal Jantung. PJNHK. Ethical Digest, No. 29, Th IV; 2007.
10. Departemen Kesehatan Republik Indonesia. Profil Kesehatan Indonesia 2008. Jakarta. 2009: 62. 11. Ghanie A. Gagal Jantung Kronik. Dalam Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam Edisi 4. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam; 2010: 1601. 53
54
12. Frishman WH, Cheng-Lai A, Nawarskas J. Current Cardiovascular Drugs. Current Science Group; 2005: 152. 13. Arcangelo VP, Peterson AM. Pharmacotherapeutics for advanced practice: a practical approach. Lippincott Williams & Wilkins; 2006: 205. 14. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ [Internet]. 1999 [cited 2013 Oct 28]; 318(7200): 1730. Available from : http://www.bmj.com/content/318/7200/1730 . 15. Cruickshank JM. β blockers in hypertension. The Lancet [Internet]. 2010 [cited
2013
Nov
1];
376(9739):
415.
Available
from
:
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)612172/fulltext. 16. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353: 9–13. 17. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERITHF). Lancet. 1999; 353: 2001–7. 18. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334: 1349–55. 19. Komajdaa M, Follath F, Swedberg K et al. The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe Part 2: treatment. Eur Heart J [Internet]. 2002 [cited 2013 Nov 1]; 24(5): 464-74. Available from : http://eurheartj.oxfordjournals.org/content/24/5/464. 20. Kalra PR, Morley C, Barnes S et al. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. International Journal of Cardiology [Internet]. 2012 [cited 2013 Nov 2]; 167(6): 2695-9. Available from
:
http://www.internationaljournalofcardiology.com/article/S0167-
5273(12)00907-2/abstract .
55
21. Regmi S, Maskey A, Dubey L. Profile of heart failure study in patients admitted in MICU. Nepalese Heart Journal. 2009; 6 : 35–8. 22. Braunwald E, Colucci WS. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, 6th ed. PA: WB Saunders; 2001: 503. 23. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112(12):e154-e235. 24. National Collaborating Centre for Chronic Conditions. Chronic heart failure. National Clinical Guideline for diagnosis and Management in Primary and Secondary Care. (Clinical Guideline
5.) London: National Institute for
Clinical Excellence (NICE); 2003:1-163. 25. Panggabean MM. Gagal Jantung. Dalam Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam. Edisi 4. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam; 2006: 1513-4. 26. Braunwald E. Heart Failure and Cor Pulmonale. Dalam Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editor. Harrison’s Principle of Internal Medicine. Edisi 16. New York: McGraw Hill; 2005: 1367-78. 27. Tierney LM; McPhee SJ, Papadakis MA. Lange, Current Medical Diagnosis and Treatment. New York: McGraw Hill; 2002: 429-30. 28. George AL Jr. Inherited disorders of voltage-gated sodium channels. J Clin Invest [Internet]. 2005 [cited 2014 Jan 20]; 115(8): 1990-9. Available from : http://www.ncbi.nlm.nih.gov/pubmed/16075039 . 29. Priori SG, Napolitano C. Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels. J Clin Invest [Internet]. 2005
[cited
2014
Jan
20];
115(8):
2033–8.
http://www.ncbi.nlm.nih.gov/pubmed/16075044 .
Available
from
:
56
30. Bonow RO, Mann DL, Zipes DP, Libby P. Pathophysiology of Heart Failure. In : Bonow RO, Mann DL, Zipes DP, Libby P, Braunwald E (eds). Braunwald's Heart Disease 9th Ed. Philadelphia: Elsevier Saunders; 2012. 494-5. 31. Bonow RO, Mann DL, Zipes DP, Libby P. Pathophysiology of Heart Failure. In : Bonow RO, Mann DL, Zipes DP, Libby P, Braunwald E (eds). Braunwald's Heart Disease 9th Ed. Philadelphia: Elsevier Saunders; 2012. 502. 32. Panggabean MM. Gagal Jantung. Dalam Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam. Edisi 4. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam; 2010: 1583-4. 33. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med [Internet]. 1971
[cited
2014
Jan
23];
285:1441–6.
Available
from
:
http://www.ncbi.nlm.nih.gov/pubmed/5122894 34. Siswanto BB, Dharma S, Juzan DA, Sukmawan R. Pedoman Tatalaksana Penyakit Kardiovaskuler di Indonesia. Jakarta: Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia. 2009: 267-8. 35. Dickenstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, et al. ESC Guideline for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008; 29: 2389-90. 36. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bӧhm M, Dickstein K, et al. ESC Guideline for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012; 33: 1791. 37. Ghanie A, Gagal Jantung Kronik. Dalam Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam. Edisi 4. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam; 2010: 1596-7. 38. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bӧhm M, Dickstein K, et al. ESC Guideline for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012; 33: 1794-803.
57
39. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bӧhm M, Dickstein K, et al. ESC Guideline for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012; 33: 1804-15. 40. Brunton LL, Blumenthal DK, Buxton IL, Parker KL. Agonis dan Antagonis Adrenergik. Dalam : Manurung J, Aini N, Hadinata AH, Fazriyah Y, Vidhayanti H, editor. Goodman and Gilman's Manual Farmakologi dan Terapi. : McGraw Hill; 2008: 161-2. 41. Chen-Izu Y, Xiao RP, Izu LT, Cheng H, Kuschel M, Spurgeon H, Lakatta EG. G(i)-dependent localization of beta(2)-adrenergic receptor signaling to Ltype Ca(2+) channels. Biophys J [Internet]. 2000 [cited 2014 Jan 25]; 79(5): 2547–56. Available from : http://www.ncbi.nlm.nih.gov/pubmed/11053129 . 42. Brunton LL, Blumenthal DK, Buxton IL, Parker KL. Agonis dan Antagonis Adrenergik. Dalam : Manurung J, Aini N, Hadinata AH, Fazriyah Y, Vidhayanti H, editor. Goodman and Gilman's Manual Farmakologi dan Terapi. : McGraw Hill; 2008: 163-70. 43. Brunton LL, Blumenthal DK, Buxton IL, Parker KL. Agonis dan Antagonis Adrenergik. Dalam : Manurung J, Aini N, Hadinata AH, Fazriyah Y, Vidhayanti H, editor. Goodman and Gilman's Manual Farmakologi dan Terapi. : McGraw Hill; 2008: 171-2. 44. Opie LH, Gersh BJ. β-Blocking Agents. In: Opie LH, Gersh BJ (eds). Drugs for the Heart 6th Ed. Philadelphia: Elsevier Saunders; 2005. 20-1. 45. Katzung BG, Masters SB, Trevor AJ. Adrenoceptor Antagonist Drugs. Basic & Clinical Pharmacology , 12th ed. : McGraw Hill; 2012: 162-4 46. Opie LH, Gersh BJ. β-Blocking Agents. In: Opie LH, Gersh BJ (eds). Drugs for the Heart 6th Ed. Philadelphia: Elsevier Saunders; 2005. 26-7. 47. Brunton LL, Blumenthal DK, Buxton IL, Parker KL. Agonis dan Antagonis Adrenergik. Dalam : Manurung J, Aini N, Hadinata AH, Fazriyah Y, Vidhayanti H, editor. Goodman and Gilman's Manual Farmakologi dan Terapi. : McGraw Hill; 2008: 170-1. 48. Opie LH, Gersh BJ. β-Blocking Agents. In: Opie LH, Gersh BJ (eds). Drugs for the Heart 6th Ed. Philadelphia: Elsevier Saunders; 2005. 15-16.
58
49. Octavian C, Albinita C, Liciniu V, Marius P. Medical And Social Care of Old Age Persons.Oradea. 2010: 1. 50. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Buch P et al.. Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes. Circulation 2007; 116: 739. Available from : http://www.circ.ahajournals.org/ (Accessed 3 July 2014). 51. Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 2014;129:e28–e292 52. Townsend N, Wickramasinghe K, Bhatnagar P et al. Coronary heart disease statistics (2012 edition). London: British Heart Foundation, 2012. Available from
:
http://www.bhf.org.uk/publications/view-
publication.aspx?ps=1002097 (Accessed 8 July 2014). 53. Ceia F, Fonseca C, Mota T et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail 2002;4:531–9. 54. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011;8:30–41. 55. Atherton JJ, Hayward CS, Wan Ahmad WA et al. Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). J Card Fail 2012;18:82–8. 56. Bocchi EA. Heart failure in South America. Curr Cardiol Rev 2013;9:147–56. 57. Global Atlas on Cardiovascular Disease Prevention and Control. Mendis S, Puska P, Norrving B editors. World Health Organization (in collaboration with the World Heart Federation and World Stroke Organization), Geneva 2011: 62. 58. Tse WY, Kendall M : Is there a role for beta-blockers in hypertensive diabetic patients? Diabet Med 1994; 11: 137-44. 59. Bell DS : Optimizing treatment of diabetes and cardiovascular disease with combined alpha,beta-blockade. Curr Med Res Opin 2005; 21: 1191-200. 60. Barnett AH, Leslie D, Watkins PJ : Can insulin-treated diabetics be given beta-adrenergic blocking drugs? BMJ 1980; 280: 976-8.
59
61. British Journal of Anaesthesia. Recommendations on perioperative b-blockers: differing guidelines: so what should the clinician do?. 2010; 104(3): 273-5. 62. Jansson S, Lie-Karlsen K, Stenqvist O, Korner U, Lundholm K, Tisell LE. Oxygen consumption in patients with hyperthyroidism before and after treatment with beta-blockade versus thyrostatic treatment: a prospective randomized study. Ann Surg. 2001;233:60–4. 63. Life
Expectancy At Birth. 2014.
Available
from
:https://www.cia.gov/library/publications/the-worldfactbook/rankorder/2102rank.html (accessed 21st July 2014). 64. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J 2013;77:2209–17. 65. Huffman MD, Prabhakaran D. Heart failure: epidemiology and prevention in India. Natl Med J India 2010;23:283–8. 66. Sasayama S. Heart disease in Asia. Circulation. 2008; 118: 2669–71. 67. Bocchi EA, Braga FG, Ferreira SM et al. [III Brazilian guidelines on chronic heart failure]. Arq Bras Cardiol. 2009; 93: 3–70.
60
Lampiran 1. Ethical Clearance
61
Lampiran 2. Izin Peminjaman Rekam Medik
62
Lampiran 3. Izin Melaksanakan Penelitian
63
Lampiran 4. Data Output SPSS Versi 22
Jenis_kelamin Cumulative Frequency Valid
laki-laki perempuan Total
Percent
Valid Percent
Percent
116
54,2
54,2
54,2
98
45,8
45,8
100,0
214
100,0
100,0
Statistics Usia N
Valid Missing
Mean
214 0 56,41
Std. Deviation
13,466
Minimum
17
Maximum
85
Klasifikasi Usia Cumulative Frequency Valid
Percent
Valid Percent
Percent
13-18
1
,5
,5
,5
19-59
133
62,1
62,1
62,6
60-64
26
12,1
12,1
74,8
65-90
54
25,2
25,2
100,0
Total
214
100,0
100,0
64
jaminan_kesehatan_sosial Cumulative Frequency Valid
ASKES
Percent
Valid Percent
Percent
80
37,4
37,4
37,4
9
4,2
4,2
41,6
41
19,2
19,2
60,7
jampersal
2
,9
,9
61,7
jamsostek
1
,5
,5
62,1
81
37,9
37,9
100,0
214
100,0
100,0
jamkesda jamkesmas
tanggungan pribadi Total
beta_blocker Cumulative Frequency Valid
bisoprolol
Percent
Valid Percent
Percent
52
24,3
24,3
24,3
1
,5
,5
24,8
1
,5
,5
25,2
12
5,6
5,6
30,8
1
,5
,5
31,3
propranolol
2
,9
,9
32,2
tidak dapat
144
67,3
67,3
99,5
1
,5
,5
100,0
214
100,0
100,0
bisoprolol (lalu distop karena syok kardiogenik) bisoprolol (lalu distop) carvedilol carvedilol (lalu distop karena hipotensi)
tidak dapat (bisoprolol diusulkan) Total
65
alasan_tidak_dapat_beta_blocker Cumulative Frequency Valid
Percent
Valid Percent
Percent
69
32,2
32,2
32,2
asma
3
1,4
1,4
33,6
bradikardia
1
,5
,5
34,1
hipotensi
5
2,3
2,3
36,4
kongesti
21
9,8
9,8
46,3
kongesti, bradikardia
1
,5
,5
46,7
syok kardiogenik
3
1,4
1,4
48,1
syok kardiogenik, kongesti
2
,9
,9
49,1
1
,5
,5
49,5
1
,5
,5
50,0
5
2,3
2,3
52,3
52
24,3
24,3
76,6
2
,9
,9
77,6
4
1,9
1,9
79,4
1
,5
,5
79,9
1
,5
,5
80,4
3
1,4
1,4
81,8
1
,5
,5
82,2
3
1,4
1,4
83,6
syok septik, cardiac arrest, terapi spironolactone sebagai diuretik curiga kongesti syok septik, kongesti terapi furosemide & spironolactone sebagai diuretik curiga kongesti terapi furosemide curiga kongesti terapi furosemide curiga kongesti, asma terapi furosemide curiga kongesti, hipotensi terapi furosemide curiga kongesti, hipotensi, bradikardia terapi furosemide curiga kongesti, terapi ivabradine curiga kontraindikasi / intoleransi beta blocker terapi HCT curiga kongesti terapi ivabradine curiga kontraindikasi / intoleransi beta blocker terapi spironolactone sebagai diuretik curiga kongesti
66
tidak diketahui
34
15,9
15,9
99,5
1
,5
,5
100,0
214
100,0
100,0
tidak diketahui (diusulkan bisoprolol) Total
furosemide Cumulative Frequency Valid
dapat
Valid Percent
Percent
116
54,2
54,2
54,2
1
,5
,5
54,7
96
44,9
44,9
99,5
1
,5
,5
100,0
214
100,0
100,0
diusulkan bila sistole >100 tidak dapat tidak dapat (diusulkan) Total
Percent
hydrochlorothiazide Cumulative Frequency Valid
dapat
Percent
Valid Percent
Percent
6
2,8
2,8
2,8
tidak dapat
208
97,2
97,2
100,0
Total
214
100,0
100,0
nitrat Cumulative Frequency Valid
dapat
Percent
Valid Percent
Percent
87
40,7
40,7
40,7
1
,5
,5
41,1
tidak dapat
126
58,9
58,9
100,0
Total
214
100,0
100,0
diusulkan jika sistole >110
67
ACE_inhibitor Cumulative Frequency Valid
captopril
Percent
Valid Percent
Percent
81
37,9
37,9
37,9
1
,5
,5
38,3
captopril (lalu distop)
5
2,3
2,3
40,7
lisinopril
5
2,3
2,3
43,0
perindopril
1
,5
,5
43,5
13
6,1
6,1
49,5
1
,5
,5
50,0
tidak dapat
107
50,0
50,0
100,0
Total
214
100,0
100,0
captopril (ditunda karena batuk)
ramipril ramipril (lalu distop)
ARB Cumulative Frequency Valid
candesartan
Percent
Valid Percent
Percent
21
9,8
9,8
9,8
candesartan (lalu distop)
2
,9
,9
10,7
irbesartan
4
1,9
1,9
12,6
1
,5
,5
13,1
telmisartan
1
,5
,5
13,6
tidak dapat
151
70,6
70,6
84,1
34
15,9
15,9
100,0
214
100,0
100,0
irbesartan diusulkan bila sistole >100
valsartan Total
Dobutamine Cumulative Frequency Valid
dapat tidak dapat tidak dapat (diusulkan) Total
Percent
Valid Percent
Percent
11
5,1
5,1
5,1
202
94,4
94,4
99,5
1
,5
,5
100,0
214
100,0
100,0
68
Digoxin Cumulative Frequency Valid
dapat
Percent
Valid Percent
Percent
89
41,6
41,6
41,6
1
,5
,5
42,1
tidak dapat
124
57,9
57,9
100,0
Total
214
100,0
100,0
dapat (lalu distop)
Spironolactone Cumulative Frequency Valid
dapat
Percent
Valid Percent
Percent
140
65,4
65,4
65,4
1
,5
,5
65,9
1
,5
,5
66,4
dapat (sebagai diuretik)
20
9,3
9,3
75,7
tidak dapat
51
23,8
23,8
99,5
1
,5
,5
100,0
214
100,0
100,0
dapat (diuretik -> normal) dapat (lalu distop)
tidak dapat (diusulkan) Total
kesesuaian_beta_blocker Cumulative Frequency Valid sesuai indikasi
Percent
Valid Percent
Percent
145
67,8
67,8
67,8
58
27,1
27,1
94,9
1
,5
,5
95,3
1
,5
,5
95,8
3
1,4
1,4
97,2
sesuai indikasi, kontraindikasi ancaman gagal nafas sesuai indikasi, kontraindikasi bradikardia sesuai indikasi, kontraindikasi hipotensi
69
sesuai indikasi, kontraindikasi kongesti tidak sesuai indikasi (dosis di bawah dosis awal) tidak sesuai indikasi (propranolol) Total
2
,9
,9
98,1
2
,9
,9
99,1
2
,9
,9
100,0
214
100,0
100,0
70
Lampiran 5. Biodata Mahasiswa Identitas Nama NIM Tempat/tanggal lahir Jenis kelamin Alamat Nomor HP e-mail
: Christian Suryajaya : 22010110120086 : Jakarta, 10 Januari 1992 : laki-laki : Jl. Melati Utara No. 7, Semarang : 0817856644 :
[email protected]
Riwayat Pendidikan Formal 1. SD : SD St. Yakobus Jakarta 2. SMP : SMP St. Yakobus Jakarta 3. SMA : SMAK 5 BPK Penabur Jakarta 4. FK UNDIP : Masuk tahun : 2010
Lulus tahun : 2004 Lulus tahun : 2007 Lulus tahun : 2010
Keanggotaan Organisasi 1. Asisten mahasiswa bagian anatomi FK UNDIP tahun 2012 s/d 2014. 2. PRMK FK UNDIP tahun 2010 s/d 2014.
